ReviewCurrent opinion in endocrinology, diabetes, and obesity2007
Androgen deprivation therapy for prostate cancer: new concepts and concerns.
Review in Current opinion in endocrinology, diabetes, and obesity, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 4 syntheses or guidelines pooled it, 158 citations in OpenAlex.
- Pooled it
- Brachytherapy Combined With or Without Hormone Therapy for Localized Prostate Cancer: A Meta-Analysis and Systematic Review.Frontiers in oncology · 2020Pooled it
- Supervised Physical Training Enhances Muscle Strength but Not Muscle Mass in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis.Frontiers in physiology · 2019Pooled it
- Pooled it
- Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer.The Journal of urology · 2011Trial
- Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study.Prostate cancer and prostatic diseases · 2011Trial
- Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy.The Journal of urology · 2009Trial
- Short term effects of GnRH agonists on plasma fibrinolytic balance in patients with advanced prostate cancer.Journal of thrombosis and thrombolysis · 2009Trial
- High-dose isoflavones do not improve metabolic and inflammatory parameters in androgen-deprived men with prostate cancer.Journal of andrologyTrial
- Intratumoral Androgens and Genetic Variants Driving Therapy Resistance in Prostate Cancer.Research (Washington, D.C.) · 2026Review
- Raised a eunuch: a case report of testicular loss without androgen replacement in a pre-pubescent boy.Annals of medicine and surgery (2012) · 2025Article
- The Impact of Triptorelin on Hormone Levels in Human and Its Metabolite Confirmation Using Liquid Chromatography-Ion Trap/Time-of-Flight Mass Spectrometry (LC/MS-IT-TOF) and Liquid Chromatography-Orbitrap (LC-Orbitrap) for Doping Control Analysis.Drug testing and analysis · 2025Article
- Reversible effect of castration induced hypogonadism on the morphology of the left coronary arteries in adult male rabbits.Anatomy & cell biology · 2024Article
- The relationship between sleep hygiene, mood, and insomnia symptoms in men with prostate cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- The Psychosocial Consequences of Prostate Cancer Treatments on Body Image, Sexuality, and Relationships.Frontiers in psychology · 2021Article
- Osteoclast inhibitor treatment among men with metastatic castration-resistant prostate cancer.Clinical oncology and research · 2018Article
- Role of androgens in cardiovascular pathology.Vascular health and risk management · 2018Review
- Cardiovascular Disease Risk Factors: How Relevant in African Men With Prostate Cancer Receiving Androgen-Deprivation Therapy?Journal of global oncology · 2017Article
- Cognitive Impacts of Estrogen Treatment in Androgen-Deprived Males: What Needs to be Resolved.Current neuropharmacology · 2017Review
- Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis.Journal of endocrinological investigation · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
purpose of reviewThe aim of this review is to summarize new concepts and concerns regarding treatment-related osteoporosis, diabetes, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. RECENT
findingsGonadotropin-releasing hormone agonists increase bone turnover, decrease bone mineral density, and increase fracture risk. Bisphosphonates, selective and estrogen receptor modulators significantly increase bone mineral density during androgen deprivation therapy. Ongoing randomized controlled trials will assess efficacy of denosumab, toremifene, and zoledronic acid to prevent fractures in this setting. Gonadotropin-releasing hormone agonists also increase fat mass, decrease insulin sensitivity, and increase serum lipoproteins. In contrast to the classical metabolic syndrome, however, the phenotype of men during androgen deprivation therapy is characterized by increased high-density lipoprotein cholesterol and preferential accumulation of subcutaneous fat. Gonadotropin-releasing hormone agonists are associated with greater risk of incident diabetes and cardiovascular disease in men with prostate cancer. SUMMARY: Androgen therapy increases risk of fractures, diabetes mellitus, and cardiovascular disease in men with prostate cancer. Current and planned studies will evaluate strategies to prevent these treatment-related adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.